Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2014; 20(1): 53-63
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.53
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.53
Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability
Danuta Owczarek, Dorota Cibor, Mikołaj K Głowacki, Tomasz Mach, Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, 31-531 Kraków, Poland
Tomasz Rodacki, Department of Bromatology, Jagiellonian University Medical College, 31-531 Kraków, Poland
Author contributions: Owczarek D reviewed the literature, wrote the paper and edited of the manuscript; Cibor D and Mach T contributed to providing the idea and performing review; Głowacki MK contributed to performing literature; and Rodacki T contributed to performing the figures.
Correspondence to: Danuta Owczarek, MD, PhD, Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland 5 Śniadeckich St, 31-531 Krakow, Poland. owczarek@su.krakow.pl
Telephone: +48-12-4247340 Fax: +48-12-4247380
Received: September 3, 2013
Revised: November 19, 2013
Accepted: December 5, 2013
Published online: January 7, 2014
Revised: November 19, 2013
Accepted: December 5, 2013
Published online: January 7, 2014
Core Tip
Core tip: Thromboembolic events (TE) in inflammatory bowel diseases (IBD) patients are often overlooked. They affect both the venous and arterial systems. The inflammatory process initiates clotting, impairs the fibrinolytic system and decreases the activity of natural anticoagulation mechanisms. Depression of anticoagulation mechanisms not only increases thrombosis, but also potentiates the inflammatory process. The objective of the present report is to demonstrate the high significance of a problem posed by hypercoagulability in IBD patients based on TE epidemiology, and to present abnormalities in the hemostatic system.